Fintel reports that on September 13, 2023, Mizuho reiterated coverage of Neurocrine Biosciences (NASDAQ:NBIX) with a Neutral recommendation.
Analyst Price Forecast Suggests 12.52% Upside
As of August 31, 2023, the average one-year price target for Neurocrine Biosciences is 128.61. The forecasts range from a low of 95.95 to a high of $161.70. The average price target represents an increase of 12.52% from its latest reported closing price of 114.30.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Neurocrine Biosciences is 1,807MM, an increase of 8.01%. The projected annual non-GAAP EPS is 3.76.
What is the Fund Sentiment?
There are 1025 funds or institutions reporting positions in Neurocrine Biosciences. This is a decrease of 88 owner(s) or 7.91% in the last quarter. Average portfolio weight of all funds dedicated to NBIX is 0.27%, a decrease of 5.06%. Total shares owned by institutions increased in the last three months by 0.20% to 102,883K shares. 
The put/call ratio of NBIX is 0.86, indicating a bullish outlook.
What are Other Shareholders Doing?
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 3,016K shares representing 3.09% ownership of the company. In it's prior filing, the firm reported owning 2,990K shares, representing an increase of 0.88%. The firm decreased its portfolio allocation in NBIX by 13.28% over the last quarter.
IJH - iShares Core S&P Mid-Cap ETF holds 2,960K shares representing 3.03% ownership of the company. In it's prior filing, the firm reported owning 2,980K shares, representing a decrease of 0.67%. The firm decreased its portfolio allocation in NBIX by 11.35% over the last quarter.
Bellevue Group holds 2,613K shares representing 2.68% ownership of the company. In it's prior filing, the firm reported owning 2,613K shares, representing a decrease of 0.02%. The firm decreased its portfolio allocation in NBIX by 8.44% over the last quarter.
NAESX - Vanguard Small-Cap Index Fund Investor Shares holds 2,519K shares representing 2.58% ownership of the company. In it's prior filing, the firm reported owning 2,528K shares, representing a decrease of 0.35%. The firm decreased its portfolio allocation in NBIX by 11.67% over the last quarter.
Jpmorgan Chase holds 1,962K shares representing 2.01% ownership of the company. In it's prior filing, the firm reported owning 2,156K shares, representing a decrease of 9.90%. The firm increased its portfolio allocation in NBIX by 502.23% over the last quarter.
Neurocrine Biosciences Background Information
(This description is provided by the company.)
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, Neurocrine Biosciences has specialized in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
